Cambrex Corp. has entered into an agreement with Lonza Group AG for the sale of its bioproducts and biopharma segments for $460 million in cash. The sale of the bio businesses, which is subject to Cambrex stockholder approval and customary regulatory approvals, is expected to close during the next few months. The bioproducts business manufactures and markets research, therapeutic and analytical testing products based on cell biology used in drug discovery and biotherapeutic manufacturing. T...